Matter Neuroscience is a technology company.
Matter Neuroscience has raised $26.0M across 1 funding round.
Matter Neuroscience has raised $26.0M in total across 1 funding round.
Matter Neuroscience is a neuroscience technology company founded in 2019 and headquartered in Boulder, Colorado, that develops tools to help individuals understand their brain chemistry—specifically neurotransmitters like dopamine—to enhance happiness, well-being, and life quality.[1][2][3] Its core product is an iOS app that enables users to track positive emotions, connect them to neurotransmitter activity, reflect on experiences, access educational content on the neuroscience of happiness, and make behavioral changes for better health.[1][2][3][5] Targeting the healthcare and wellness sector, Matter serves consumers seeking personalized insights into their "biological reward systems" amid a global mental health crisis affecting over 200 million people with major depressive disorders; the company has raised $26M in Series A funding (last round in 2024), signaling strong early momentum from biotech investors.[1][3]
Matter Neuroscience emerged in 2019 from a mission to bridge neuroscience research with everyday life, co-founded by biochemist and neuroscientist Axel Bouchon—a veteran biotech executive who led venture arms at Moderna and Bayer and serves as an ARCH Venture partner—alongside Ben Goldhirsh (of GOOD Worldwide and the Goldhirsh Foundation) and Chris Shiflett (of Faculty and Brooklyn Beta).[1][2][3] The idea stemmed from recognizing that while philosophers and scientists have long studied happiness, modern society prioritizes material success over emotional well-being, leaving people without tools to decode their internal "molecular" signals for joy.[3] Early partnerships with Maastricht University, the Happiness Research Institute, and Icahn School of Medicine at Mount Sinai fueled research into universal biomarkers for happiness, leading to the app's launch as the first consumer product; pivotal validation came from initial studies showing a "universal map of distinct positive emotions" in the brain, attracting $26M from investors like ARCH Venture Partners and Polaris Partners.[1][2]
Matter Neuroscience rides the intersection of neuroscience, mental health tech, and personalized wellness, capitalizing on post-pandemic awareness of a mental health crisis (200M+ with depression) and advances in biomarker research for emotions.[1][3] Timing is ideal amid booming digital health apps and AI-driven personalization, with market forces like rising demand for non-pharmacological well-being tools (e.g., beyond therapy or meds) favoring its molecular approach—early studies confirm neurotransmitter patterns as reliable happiness indicators.[1][2] By democratizing lab insights via an app, Matter influences the ecosystem, pushing competitors toward science-validated models and fostering a shift from tracking symptoms to optimizing joy, potentially accelerating "happiness tech" adoption in healthcare.[3][5]
With $26M secured and app metrics showing thousands of user memories logged, Matter is poised to expand beyond iOS—potentially adding Android, wearables integration, or at-home neurochemical testing—to scale its biomarker platform.[1][5] Trends like AI-enhanced brain mapping and corporate wellness programs will propel growth, evolving its influence from niche app to ecosystem leader in proactive happiness engineering. As neuroscience demystifies what truly "matters," Matter could redefine well-being, turning elusive joy into a measurable, optimizable pursuit for millions.[3]
Matter Neuroscience has raised $26.0M in total across 1 funding round.
Matter Neuroscience's investors include ARCH Venture Partners, Avalon Ventures, Broadview Ventures, Polaris Partners, Versant Ventures.
Matter Neuroscience has raised $26.0M across 1 funding round. Most recently, it raised $26.0M Seed in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $26.0M Seed | ARCH Venture Partners, Avalon Ventures, Broadview Ventures, Polaris Partners, Versant Ventures |